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Summary 
Synthetic, natural, or composite, biomaterials occupy a key position in the 
management of disease and support continuous advancement of health 
care. Clinical utility of many permanent and biodegradable implants can 
be significantly improved via surface modification. Here, we discuss a 
novel polymer material developed from essential oil-based monoterpene 
alcohol using plasma polymerisation. The developed coatings are 
cytocompatible and limit adhesion and proliferation of a variety of 
pathogens. The coating can also be used to control degradation behaviour 
of resorbable materials, such as magnesium. 
 
Introduction 
In addition to being fundamental components of extracorporeal and 
indwelling devices and delivery vehicles for pharmaceutical preparations, 
biomaterials are also instrumental for ex vivo cell and tissue culturing, 
biomolecule testing and processing, and diagnostics. While physical 
properties of biomaterials may match or even supersede that of the tissues 
they are designed to replace, their biocompatibility and bioactivity is yet to 
be sufficient to attain full integration. Relatively high hydrophobicity of 
these materials impedes their ability to interact with the physiological 
environment, potentially leading to irregular tissue response, whilst high 
friction increases the tissue damage during device implantation, positively 
contributing to inflammation and hindering wound healing. Furthermore, 
many biomaterials have been adopted for medical applications from other 
industries, with the choice being primarily guided by the bulk mechanical 
properties and chemical inertness of these materials. For example, 
favourable mechanical characteristics, especially fracture toughness and 
fatigue strength, bioinertness and resistance to electrochemical oxidation 
of titanium and its alloys, and cobalt based alloys make these metallic 
biomaterials well suited to load bearing long term implantation, including 
total joint arthroplasty and restorative dentistry.  
Even those materials designed specifically for biomedical applications 
may not necessarily display the required level of biological activity. The 
interactions between living and abiotic phases, and between different types 
of living tissues are highly dynamic and exceedingly complex, making 
them hard to fully characterise and mimic. Time dependent material 
degradation and consequent deterioration of mechanical strength, changes 
in surface physico-chemical characteristics, leaching of potentially toxic 
ions and wear particles into peri-implant milieu may be detrimental to the 
ability of the implant to correctly perform its intended function. Even 
relatively inert titanium and chromium-based biomaterials have been 
shown to undergo in vivo corrosion, leaching ions and particulate debris. 
Furthermore, long term implantation increases the chances of the 
indwelling devices to undergo such adverse physiological reactions as 
chronic inflammation, adjacent tissue resorption and late thrombosis [1].  
Over the recent years, significant progress has been made in the 
development of bioresorbable implantable devices. The approach relies on 
the ability of tissues to undergo regeneration, with the implantable 
structures required to provide only a temporary support and then safely 
break down without the need for the removal surgery. For example, 
degradable implants for internal fixation of bones, such as screws and 
plates, are used to maintain the corrected alignment of the elements in 
fractured bone for the period required for tissue to fully re-grow. A similar 
approach is used for function restoration, such as in the case of the 
abnormal narrowing of the tubular vessels within the human body. There, 
a stent is surgically inserted into the narrowed vessel to restore flow and 
mechanically support the walls of the vessel through the regeneration 
process. Magnesium and its alloys are among the materials well suited to 
load bearing tissue regeneration and function restoration uses, due to their 
high biocompatibility, non-toxicity, high primary stability and tensile 
strength, and fracture toughness. Yet, fast in vivo degradation of these 
materials, with ensuing rapid release of a large amounts of Mg ions, 
localised build up of hydrogen gas and alkalization, and an premature loss 
of mechanical strength of the implanted structure, limit their clinical utility 
[2]. To meet clinical requirements, precise control over in vivo degradation 
of such implants is essential, especially at early stages of implantation 
where the degradation has been suggested to be most pronounced. 
Infections continue to be of a significant concern for most 
extracorporeal and indwelling devices, with bacterial attachment and 
subsequent biofilm formation being the principal reason for device 
associated infections and device failure. While the most common route of 
acquiring the pathogen is direct contamination of the implant during 
handling, surgery, and post-operative care, pathogens can also be spread 
from an infection site elsewhere in the body via blood to cause a late 
haematogenous infection. Depending on the severity of infection, 
associated symptoms, and patients’ clinical status, a course of antibiotics 
and/or surgical device removal may be necessary. Typically, systemic 
antibiotics are administered intravenously, orally or intramuscularly in a 
dose and for a period sufficient to establish serum and tissue levels 
required to eliminate the target pathogen. Recently, however, there has 
been a significant rise in the antibiotic resistant pathogens, such as 
methicillin-resistant S. aureus, responsible for serious nosocomial 
infections. Such quickly diminishing effectiveness of systemic antibiotics 
against nosocomial pathogens further undermine healing, at a high cost to 
healthcare and patients. For instance, orthopaedic surgical site infections 
prolong total hospital stays by two weeks, double rehospitalisation rates, 
and increase costs by over 300%. Furthermore, patients may experience 
pain and an overall decline in quality of life. Given the economic 
implications of the ever increasing population longevity, there is a strong 
need for economical biomaterial solutions that combine biocompatibility 
with antimicrobial effectiveness. 
 
Surface modification and encapsulation 
Recent advances in characterisation and visualisation techniques 
resulted in deeper understanding of the interactions that take place at the 
abiotic surface/tissue interface, emphasizing the importance of surface 
properties of biomaterials in determining the response of the biological 
environment to the implant. Based on these findings, a host of new 
methods capable of tailoring the chemical, physical, and biological 
characteristics of the biomaterials have been developed. While some of the 
methods involve synthesis of a new material with desirable functions built 
into its matrix, others employ surface modification of presently available 
biomaterials. In addition to being fast and economical, the latter approach 
allows for the attainment of desired biocompatibility and biofunctionality 
of the material, while preserving its favourable bulk characteristics such as 
strength and inertness. Amid plentiful methodologies of surface 
modification, plasma surface treatment is a flexible and environmentally 
friendly process used to alter the surface morphology, structure, 
composition, and properties of the material to a specific need. Plasma 
surface treatment typically involves a biomaterial being exposed to a 
reactive environment of a partially ionised gas (called plasma), which 
consist of large concentrations of excited atomic, molecular, ionic, and 
free-radical species. Typically, non-equilibrium plasmas are employed, 
since they can be initiated at low temperatures suitable for surface 
cleaning and functionalisation of temperature-sensitive materials, such as 
polymers and thin film devices.  
Depending on the nature of interactions between the plasma species 
and the treated surface, a varying degree of chemical and physical 
modification can be attained. By controlling the pressure inside the plasma 
chamber, the magnitude and the manner in which the energy is delivered, 
the feed gas, and other processing conditions, the treatment may result in 
ablation, chemical substitution, or film deposition. The latter occur when a 
monomer, delivered to the chamber as a vapour/gas or at the surface, 
undergoes fragmentation. The reactive fragments then undergo 
recombination, forming a polymer-like layer on the surface of the 
material. Even those monomers that do not undergo conventional 
polymerisation can be fabricated into thin films using this technique. The 
material and biological properties of the layers, as well as their 
degradation kinetics can be controlled by varying the processing 
conditions during deposition. For medical applications, these coatings 
typically combine biocompatibility with other biological functions, such 
as the capacity to prevent bacterial attachment and subsequent biofilm 
formation, kill attached microorganisms, support and promote selective 
protein attachment, induce cell adhesion and tissue healing.  
Feed gases that do not undergo fragmentation into polymerisable 
intermediates upon excitation, such as nitrogen, argon, and oxygen, are 
typically employed to sterilise the surface, ablate, cross-link or activate the 
surface, and introduce specific functional groups. For example, plasma-
assisted oxidation, nitration, hydrolyzation, or amination is typically 
employed to increase the surface energy and improve hydrophilicity of the 
biomaterial, thus altering the manner in which the surface interacts with 
living phase. Furthermore, exposure to plasma has an added benefit of 
surface sterilisation, being effective against a host of medically relevant 
microorganisms, including E. coli, S. aureus, and P. aeruginosa [3]. 
 
Essential oil-based encapsulation materials 
Essential oils and oil-based compounds have long been known for their 
anti-inflammatory properties and broad-spectrum antimicrobial activity. 
The antibacterial, antifungal and antiviral properties of Melaleuca 
alternifolia (tea tree) oil are well documented. Terpinen-4-ol is a major 
constituent of tea tree oil and several other essential oils, thought to be 
responsible for the anti bacterial efficacy of tea tree oil. Treatment of S. 
aureus cells with liquid terpinen-4-ol resulted in the damage to the cell 
membrane, characterised by the presence of mesosomes and a loss of 
cytoplasmic material. It is believed that cyclic terpene hydrocarbons 
accumulate in the cytoplasmic membrane of bacteria, causing a loss of 
membrane integrity which ensuing increase in the passive flux of protons 
across the membrane and dissipation of the proton motive force. 
Nevertheless, the commercial applications for these oils are typically 
limited to the formulation of food flavouring, fragrance/cosmetics, 
pharmaceuticals, and industrial solvents.  
 
Figure 1. Representative images of live (green) and dead (red) S. aureus 
cells on polished (left) and polymer-encapsulated (right) titanium surfaces. 
Recently, we demonstrated the possibility of fabricating thin film 
coatings from essential oils and their individual constituents using non-
equilibrium radio frequency plasma polymerisation. These coatings are 
highly uniform and defect free, with sounds adherence to a variety of 
substrates, including metals, plastics, and glasses. By varying deposition 
conditions, in particular the energy used to sustain the plasma field, the 
physico-chemical, mechanical and surface properties of these essential oil-
based materials can be controlled. Monoterpene alcohol coatings produced 
at low input powers have been demonstrated as potential antimicrobial 
coatings capable of limiting adhesion, proliferation and biofilm formation 
of P. aeruginosa, S. aureus and S. epidermidis [4, 5], as shown in Figure 
1. Under these conditions, the process allows for retention of a significant 
degree of chemical functionalities pertinent to the original molecule. 
Reduced energy intensity (just sufficient enough to initiate dissociation) 
results in less fragmentation of the molecule, with recombination process 
resembling conventional polymerisation, and also favours the entrapment 
of unfragmented molecules within the polymer matrix. 
The cytocompatibility of these coatings was demonstrated using non-
adherent human cells (HTP-1 cell line), where cells incubated in the 
presence of polymer-coated and unmodified inert glass showing similar 
growth rate and viability of approximately 95–98 %. Likewise, BALB/c 
mouse macrophages and osteoblasts grown on the unmodified and 
polymer-coated surfaces demonstrated similar viability, good adhesion, 
and a healthy well spread morphology (Figure 2). Macrophages stimulated 
with E. coli lipopolysaccharides were shown to attach more readily to 
polymer-coated surfaces, also displaying better conformation on these 
surfaces.  
 
Figure 2. The attachment of osteoblasts onto the surface of terpene-4-ol 
coated TiNi (left) and Ti (right) substrates. The bar is 20 μm. 
Encapsulation of magnesium disks using the developed coating notably 
reduced the degradation rate of the material under simulated body fluid 
conditions, suggesting it as a suitable method for controlling in vivo 
biodegradation of the material. The viability of HTP-1 cells was also 
significantly improved when grown in the presence of polymer-coated 
versus unmodified magnesium, at 85 % and 30 %, respectively.  
 
Conclusions 
Coatings fabricated from essential oil-based compounds using RF plasma 
polymerisation combine attractive physico-chemical properties and good 
adhesion to a variety of substrates with sound cytocompatibility and 
ability to limit attachment and proliferation of several clinically relevant 
pathogens. These coatings may be a potential candidate for surface 
biomodification of resorbable implantable metals. 
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